Abstract：Objective To study the clinical effect on heart failure patients with intravenous use of levosimendan.Methods We collected 60 cases of heart failure patients from January 2012 to January 2014, including 30 cases with ischemic cardiomyopathy and 30 with dilated cardiomyopathy. Since conventional drugs did not work, these patients were given intravenous injection of levosimendan. According to the instructions, the initial loading dose was 12 μg/kg in 10 minutes, and then continuous dose remained to be 0.1 μg·kg-1·min-1.For heart failure patients, the clinical efficacy of levosimendan was evaluated by comparing the improvements of some indexes 48 hours after the drug therapy and before. The indexes included left ventricular ejection fraction(LVEF), stroke volume(SV), and N-terminal brain natriuretic peptide(NT-BNP). Results The mean value of LVEF increased by 6.41% 48 hours after the treatment than before, and the difference was statistically significant(P＜0.05). The increase of LVEF in ischemic cardiomyopathy group(increase by 8.32%) was significantly higher than that in dilated cardiomyopathy group(increase by 4.5%), and the difference was statistically significant(P＜0.05). The average increase of SV was 13.91 mL after the treatment, and the difference was statistically significant if (P＜0.05) if compared with SV value before the processing. The average increase of SV in ischemic cardiomyopathy group(17.56 mL) was significantly higher than that in dilated cardiomyopathy group(10.26 mL), and the difference was statistically significant(P＜0.05). The average decrease of NTBNP was 4 051 pg/mL after the treatment, and the difference was statistically significant if (P＜0.05) if compared with the value before the processing. With the use of levosimendan, dyspnea was relieved and the overall physical status of heart failure patients was improved significantly.Conclusion Compared with routine treatment, intravenous use of levosimendan proves to be effective in patients with severe decompensated heart failure. It ameliorates hemodynamics indexes of ischemic cardiomyopathy patients better than those of dilated cardiomyopathy cases.
\[1\] Dec GW.Acute decompensated heart failure:the shrinking role of inotropic therapy\[J\].J Am Coll Cardiol,2005,46(1)：65-67.\[2\] Cleland JG，Ghosh J，Freemantle N，et al. Clinical trialsupdate and cumulative metaanalyses from the American College of Cardiology：WATCH，SCDHeFT，DINAMIT，CASINO，INSPIRE，STRATUSUS，RIOLipids and cardiac resynchronisation therapy in heart failure \[J\].Eur J Heart Fail，2004，6（4）：501-508.\[3\] Toller WG,Stranz C.Levosimendan, a new inotropic and vasodilator agent\[J\].Anesthesiology,2006,104(3):556-569.\[4\] McMurray JJ，Pfeffer MA.Heart failure\[J\].Lancet,2005,365(9474):1877-1889.\[5\] 郑爱娣, 王咏梅, 徐静.左西孟旦治疗急性心肌梗死后心力衰竭的临床观察与护理\[J\].心脑血管病防治，2013，13（3）：250-251.\[6\] 杨延民，孙志桂，许传祥.左西孟旦治疗失代偿性心力衰竭患者的临床疗效观察\[J\].中国现代医生，2014，52 （9）：52-54.\[7\] Follath F. Newer treatments for decompensated heart failure:focus on levosimendan\[J\].Drug Des Devel Ther,2009,3:73-78.\[8\] Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes \[ J\]. Am J Cardiol,2005,96(6A):68G-73G.\[9\] CohenSolal A,Logeart D,Huang B,et al.Lowered Btype natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure\[J\].J Am Coll Cardiol,2009,53(25):2343-2348.\[10\] 张力俨，赵友民，陆晓.左西孟旦治疗急性充血性心力衰竭的临床观察\[J\].中国当代医药，2013，20（17）：99-100.
2014, Vol. 23 
